Detail

Chr	chr11
start	1995176
end	2001470
lncRNA name	H19
entrez id	283120
hgnc id	HGNC:4713
ensg id	ENSG00000130600
refseq id	NR_002196
methods	Microarray, qPCR, Western blot, RNAi etc.
regulated	up-regulated
function description	we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down. Moreover, we found that CUL4A, an ubiquitin ligase component, was a critical factor bridging H19 lncRNA to MDR1 expression, and a high tumor CUL4A expression was associated with low survival in breast cancer patients treated with chemotherapy. A similar trend was observed in ER-positive breast cancer patients treated with chemotherapy although it was not statistically significant in overall survival due to a small sample size
pubmed id	29190892
year	2017
title	LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway.
drug	X
circulating	X
survival	V